Ventripoint Diagnostics Announces New Marketing Manager and Provides
Corporate Update on Sales
Toronto, Ontario, October 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Jessica Naman has joined Ventripoint as Marketing Manager and will be responsible for conceiving and executing marketing strategies and tactics for the growth of the current VMS+ system along with the rollout and expansion of the next generation product line.
Jessica is implementing a comprehensive corporate branding strategy to enhance Ventripoint’s recognition as a global leader in whole-heart analysis through the development of public relations, interactive online media and creative strategies. She will be leading the team in the pre-launch plan as we showcase the next generation system at EuroEcho 2018 in Milan, Italy this December, and will explore further opportunities in the future of 3D heart analysis using conventional 2D ultrasound technologies.
“Jessica will be responsible for translating the Company’s business objectives into marketing strategies that drive revenue. With 15 years of experience in marketing for technology-based companies, most recently in the medical device industry, she brings a proven track record in the development and management of comprehensive marketing campaigns, which integrate a strategic approach to public relations, social media, conferences and events,” commented Desmond Hirson, President of Ventripoint.
The Company has secured two new orders for its VMS+ heart analysis products at leading hospitals in Germany and the United States (more details will follow). Furthermore, an additional cardiac centre in Canada is in the final stages of institutional signoffs prior to issuing a purchase order. The sales funnel has also expanded with 12 clinical studies being planned to show the merits of the VMS+ approach to cardiac analysis in specific heart conditions including pregnancy, stress tests, right heart failure, left heart failure, along with congenital heart disease in children and adults, and pulmonary hypertension. In addition, our sales team will be delivering several presentations to pediatric cardiologists across North America and Europe on the VMS+ products.
“The immediate recognition of the value the VMS+ in many clinical settings by leading cardiologists, speaks to the unmet need for accurate and precise whole heart analysis,” stated Dr. George Adams, CEO of Ventripoint. “Therefore, our sales and marketing strategy is to engage the leading cardiac centres and build the clinical case for the routine use of the VMS+.”
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. In particular, this news release contains forward-looking information relating to the Offering and the use of the proceeds therefrom. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation, including expectations and assumptions concerning the completion of the second tranche of the Offering and the use of net proceeds of the Offering. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because the Corporation can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Such factors may include the failure to successfully market the Units and failure to satisfy certain conditions in connection with the issuance of the Units. Other factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.